---
title: "Evolution in AAV Process Development: 2022 and Beyond"
description: "Download this whitepaper to learn the answers to these questions and much more:\nWhat are the key areas of uncertainty for the gene therapy industry at present?\nWhat have been the key advances in AAV manufacturing technology over the past two years?\nWhat are the key pathways forward on the bioprocess side if the field is to address toxicity concerns?"
image: https://go.technologynetworks.com/hubfs/Technology%20Networks/Landing%20Pages/Thermo/Jessica/February%20250%20SQL/istockphoto-1213713667-612x612.jpg
---

![WhiteOneLine](https://go.technologynetworks.com/hubfs/Technology%20Networks/Logos/WhiteOneLine.png "WhiteOneLine")

![WhiteOneLine](https://go.technologynetworks.com/hs-fs/hubfs/Technology%20Networks/Logos/WhiteOneLine.png?width=300&height=30&name=WhiteOneLine.png "WhiteOneLine")

![TN_Stacked_White-1](https://go.technologynetworks.com/hubfs/Imported%20images/TN_Stacked_White-1.png "TN_Stacked_White-1")

Whitepaper

# Evolution in AAV Process Development: 2022 and Beyond

![smartmockups_kzidpv0f](https://go.technologynetworks.com/hs-fs/hubfs/Technology%20Networks/Landing%20Pages/Thermo/Jessica/February%20250%20SQL/smartmockups_kzidpv0f.png?width=400&name=smartmockups_kzidpv0f.png)Over the last decade, the number of clinical trials involving recombinant adeno-associated viral (AAV) vectors has dramatically increased, the diversity of serotypes has expanded and the demand for larger quantities of highly purified material manufactured to cGMP standards has rocketed.

In 2019, BioInsights hosted a popular roundtable video and article with leading experts in AAV vector process development. Two eventful years later, the panel has been brought back together to discuss how viral vector manufacture is evolving and what we can expect in the future.

**Download this whitepaper to learn the answers to these questions and much more:**

- What are the key areas of uncertainty for the gene therapy industry at present?
- What have been the key advances in AAV manufacturing technology over the past two years?
- What are the key pathways forward on the bioprocess side if the field is to address toxicity concerns?

**Brought to you by:**

 

**![Thermo Fisher](https://go.technologynetworks.com/hs-fs/hubfs/Images/TS/emails/2017%20Innovations/Thermo%20Fisher.png?width=182&name=Thermo%20Fisher.png)**

 

 

**Download this whitepaper to learn the answers to these questions and much more:**

- What are the key areas of uncertainty for the gene therapy industry at present?
- What have been the key advances in AAV manufacturing technology over the past two years?
- What are the key pathways forward on the bioprocess side if the field is to address toxicity concerns?

Access this Whitepaper for FREE Now!

![TN_Stacked](https://go.technologynetworks.com/hubfs/Imported%20images/TN_Stacked.svg "TN_Stacked")

Technology Networks Limited   
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK   
Email: privacy@technologynetworks.com   
© 2022 Technology Networks. All rights reserved

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our [Privacy Policy](https://www.technologynetworks.com/tn/privacy)

This content is copyright protected. Any public or private use of this content is subject to prevailing copyright laws. Please contact [Technology Networks](https://www.technologynetworks.com/tn/copyright) for permission requests.